Altaris Acquires Simulations Plus for $375 Million, Exits Nasdaq

Private equity firm Altaris Capital Partners agreed to acquire Simulations Plus for approximately $375 million in an all-cash transaction. SeekingAlpha reported the deal on Monday, 16 June 2026. The transaction values the provider of artificial intelligence-driven drug discovery and development software at $10.50 per share, representing a 28% premium over its closing price on Friday, 13 June. Simulations Plus stock ceased trading on the Nasdaq following the announcement, concluding its 28-year run as a public company.

Context — why this matters now

This transaction highlights the sustained private equity interest in specialized healthcare technology platforms. The last comparable deal in the sector saw Certara, a Simulations Plus competitor, go private in a $2.8 billion transaction with EQT in August 2025. That premium was 24% over the unaffected share price.

Deal activity in life sciences software has accelerated against a backdrop of stable interest rates, with the Federal Funds target rate holding at 4.75-5.00%. This stability provides private equity firms with clearer financing costs for leveraged buyouts.

The primary catalyst for the acquisition is the maturation of AI applications in biopharma R&D. Simulations Plus's software, including its flagship GastroPlus and PK/PD modeling platforms, is integral to modern clinical trial design. Altaris identified an opportunity to acquire a cash-generative asset in a niche where demand is structurally rising, yet public market valuations have lagged behind private market multiples.

Data — what the numbers show

The $375 million enterprise value represents a 28% premium to Simulations Plus's unaffected closing price of $8.20 on Friday. The table below compares key valuation metrics before and after the announcement.

Metric	Pre-announcement (13 Jun)	Deal Value (16 Jun)
Share Price	$8.20	$10.50
Market Capitalization	~$293M	~$375M
52-week high	$10.02	N/A

The $10.50 per share price is 4.8% above the stock's 52-week high of $10.02, set in January 2026. The deal values Simulations Plus at roughly 4.5 times its trailing twelve-month revenue of $83 million. This multiple is a discount to Certara's 5.2x revenue multiple in its 2025 buyout but is broadly in line with the sector median for profitable software firms.

Simulations Plus reported net income of $12.1 million for its last fiscal year. The company ended its most recent quarter with $62 million in cash and no debt, making it a clean target for a leveraged acquisition.

Analysis — what it means for markets / sectors / tickers

The acquisition provides immediate positive price validation for other public companies in the computer-aided drug design space. Direct peers like Schrödinger saw their shares rise 3.7% in early trading on the deal news, as the market reprices the segment. Suppliers to the AI drug discovery ecosystem, such as software vendors using similar machine learning architectures, may also see increased investor interest.

A key risk to the bullish sector read-through is that Simulations Plus was uniquely profitable. Many AI drug discovery firms are still revenue-growth stories with significant cash burn. Private equity may remain selective, favoring companies with proven monetization over speculative technology.

Institutional flow data indicates some rotation from the acquired name into smaller-cap peers like Recursion Pharmaceuticals and BenevolentAI. The deal also signals to hedge funds that the healthcare technology sector is ripe for further consolidation, potentially leading to increased long-short pair trading strategies.

Outlook — what to watch next

Market participants will monitor the closing of the deal, expected in Q4 2026. Any regulatory scrutiny from the FTC regarding market concentration in life science software would be a key delay risk.

Attention shifts to whether other private equity firms or strategic buyers like Thermo Fisher Scientific respond with competing bids. The merger agreement includes a 30-day go-shop period, allowing Simulations Plus to solicit superior offers.

For the broader sector, watch the performance of the iShares Genomics Immunology and Healthcare ETF. A sustained break above its 200-day moving average of $48.50 could signal renewed institutional conviction in the theme catalyzed by this M&A activity.

Frequently Asked Questions

What does the Simulations Plus acquisition mean for retail shareholders?

Individual shareholders of Simulations Plus will receive $10.50 in cash for each share they own upon the deal's closing, expected later in 2026. No further action is required, and the stock will be delisted. The premium offers a definitive exit, but shareholders miss out on any future upside if the company's value grows under private ownership.

How does this deal compare to other recent biotech software buyouts?

The $375 million valuation is smaller than the $2.8 billion Certara deal but carries a higher premium at 28% versus 24%. The revenue multiple of 4.5x is slightly below the sector's recent average, reflecting Simulations Plus's slower growth profile compared to some cloud-native platforms. It fits a pattern of private equity consolidating established, cash-flow positive players in niche healthcare IT markets.

What is Simulations Plus's main business and who are its clients?

Simulations Plus develops AI and machine learning software for pharmaceutical and biotechnology companies. Its main products simulate how drugs are absorbed, distributed, metabolized, and excreted in the body. Major clients include Pfizer, Merck, and Novartis, who use the software to predict clinical trial outcomes, potentially saving hundreds of millions in development costs and reducing late-stage failures.

Bottom Line

The deal validates the strategic value of profitable, AI-enabled drug development software as a core asset for private capital.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.